AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
NCT ID: NCT03732794
Last Updated: 2024-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
150 participants
INTERVENTIONAL
2019-01-30
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of Left Atrial Appendage Occlusion
NCT00567515
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
NCT02701062
Stroke Feasibility Study
NCT01997905
AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB
NCT00571779
VCLIP Post-Market Study, Long-term Follow-up on LAA Exclusion Using AtriClip
NCT05101993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The effectiveness of the device will be demonstrated by establishing that the device effectively eliminates persistent and long-standing persistent atrial fibrillation in a clinically significant proportion of treated patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has history of persistent or long-standing persistent atrial fibrillation as defined by the 2017 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/ European Cardiac Arrhythmia Society (ECAS) Guidelines
3. Stable Subject that is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or replacement, and Coronary artery bypass procedures
4. Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
5. Subject is willing and able to provide written informed consent
6. Subject has a life expectancy of at least 5 years
7. Subject is willing and able to return for scheduled follow-up visits.
Exclusion Criteria
2. Previous surgical Maze procedure
3. Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, Atrioventricular (AV) nodal reentry
4. Prior cardiac surgery (Redo)
5. Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or patent foramen ovale repair, and/or atrial septal defect repair.
6. Class IV New York Heart Association (NYHA) heart failure symptoms
7. Prior history of cerebrovascular accident within 6 months or at any time if there is residual neurological deficit
8. Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
9. Need for emergent cardiac surgery (i.e. cardiogenic shock)
10. Known carotid artery stenosis greater than 80%
11. Documented AF duration of greater than ten years
12. LA diameter \>7 cm by Transthoracic echocardiography (TTE)
13. Current diagnosis of active systemic infection
14. Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
15. Renal failure requiring dialysis or hepatic failure
16. A known drug and/or alcohol addiction
17. Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study
18. Pregnancy or desire to get pregnant within 12-months of the study treatment
19. Preoperative need for an intra-aortic balloon pump or intravenous inotropes
20. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia
21. Subjects who have been treated with thoracic radiation
22. Subjects in current chemotherapy
23. Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases)
24. Subjects with known connective tissue disorders
25. Subjects with known hypertrophic obstructive cardiomyopathy
26. Subjects with known cold agglutinin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AtriCure, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niv Ad, MD
Role: PRINCIPAL_INVESTIGATOR
Washington Adventist Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Medical Center
Los Angeles, California, United States
Washington Adventist Hospital
Washington D.C., District of Columbia, United States
Northwestern Medicine
Chicago, Illinois, United States
Franciscan Health
Indianapolis, Indiana, United States
Deaconess Gateway Hospital
Newburgh, Indiana, United States
University Of Maryland
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
St. Luke's Hospital
Kansas City, Missouri, United States
Mount Sinai Icahn School of Medicine
New York, New York, United States
NYP-Weill Cornell
New York, New York, United States
Northwell Health Systems
New York, New York, United States
St. Joseph Hospital Health Center
Syracuse, New York, United States
St Thomas West Hospital
Nashville, Tennessee, United States
West Virginia University
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP2018-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.